In cases of established tumors, while a single Xcl1-E6E7 dose achieved tumor suppression, it was not curative, with recurrences observed, whereas the E6E7 group exhibited even weaker anti-tumor effects under this condition (Figure 4A–C). This evidence concerns the gene XCL1 and neoplasm.